Japan/China biopharma developer of fibrosis treatments, with a Phase III liver-fibrosis drug via Chinese subsidiary Beijing Continent.
Japan/China biopharma developer of fibrosis treatments, with a Phase III liver-fibrosis drug via Chinese subsidiary Beijing Continent.
Earns mostly from selling Etuary, its pirfenidone drug for lung fibrosis, in China, with those sales funding development of F351, its liver-fibrosis candidate in late-stage trials. Most operations and revenue sit in China through its subsidiary, though the parent is listed in Japan.
In one line: A Japan-listed biotech with its main pipeline running through a Chinese subsidiary.
Moat: narrow (IP / patents, regulatory licence). Late-stage fibrosis drug candidates and a China-approved subsidiary give a scarce pipeline position.
Headquarters: Tokyo, Japan · Founded: 1990 · Employees: 990
Size GNI (2160.T) is a Japan Health Care company (Biotechnology) with a market value of $903M, the 781st largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥2,228 on 18 Nov 2026.
Performance Over six months the shares fell 24.6%, against -16.5% for the median peer and -1.4% for the Japan market (cap-weighted) — 8th lowest of 21 in its peer set.
Growth Revenue grew 44.4% over the last twelve months (peer median +1.1%); the operating margin is -21.2% (peer median -45.3%).
Valuation It trades at 143.0× forward earnings against a peer median of 29.2× (most expensive of 7).
Capital Return on invested capital runs 13.7 points below its cost of capital (10.6% WACC).
Next results Next results expected around 17 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥37.2B | ¥26.8B | ¥23.6B | ¥26.0B | ¥17.4B |
| Revenue growth | — | +14% | -9% | +49% | — |
| Gross profit | ¥23.5B | ¥20.0B | ¥18.0B | ¥22.4B | ¥14.7B |
| EBITDA | -¥5.64B | -¥1.16B | ¥437M | ¥5.19B | ¥1.76B |
| Net income | -¥7.79B | -¥4.24B | ¥1.10B | ¥8.09B | ¥389M |
| Free cash flow | -¥10.2B | -¥2.74B | -¥3.69B | ¥5.28B | -¥580M |
| Capital expenditure | ¥4.29B | ¥1.56B | ¥1.54B | ¥2.08B | ¥1.94B |
| Total debt | ¥83.9B | ¥22.2B | ¥22.7B | ¥18.8B | ¥10.2B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| GNI 2160.T | $903M | -25% | +44% | -21% | 143.0× | n/a |
| Keymed Biosciences 2162.HK | $2.39B | +7% | 0% | -73% | 18.2× | n/a |
| Shionogi & 4507.T | $17.6B | +3% | +46% | 29% | 11.8× | 0.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2160.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -21.8% | -8.8% | 6th lowest of 21 |
| 6-month return | -24.6% | -16.5% | 8th lowest of 21 |
| Distance from 52-week high | -40.4% | -41.8% | 10th highest of 21 |
| Revenue growth (TTM) | +44.4% | +1.1% | 4th highest of 18 |
| Operating margin | -21.2% | -45.3% | 9th highest of 19 |
| Forward P/E | 143.0× | 29.2× | most expensive of 7 |
| ROIC minus cost of capital | -13.7 pp | -8.9 pp | 4th lowest of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| GNI 2160.T | Japan | $903M | -25% | +44% | -21% | 143.0× | n/a | n/a |
| Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZ | China | $909M | -15% | 0% | 22% | 21.6× | 9.2% | +2.3% |
| Odyssey Therapeutics ODTX | United States | $912M | +12% | -33% | -5,415% | n/a | n/a | n/a |
| Innovita Biological Technology 688253.SS | China | $915M | -28% | -28% | 11% | 92.6× | 39.6% | -16.6% |
| China Animal Husbandry Industry 600195.SS | China | $921M | -16% | +1% | 2% | 41.5× | 6.1% | +4.4% |
| Peptidream 4587.T | Japan | $878M | -3% | +14% | -18% | 29.9× | n/a | n/a |
| Verastem VSTM | United States | $866M | +66% | +650% | -194% | n/a | n/a | n/a |
| Oxford BioMedica OXB.L | United Kingdom | $841M | -15% | +16% | -18% | n/a | n/a | n/a |
| Changchun BCHT Biotechnology 688276.SS | China | $992M | -2% | +2% | -29% | n/a | n/a | n/a |
| SpyGlass Pharma SGP | United States | $993M | +36% | n/a | n/a | n/a | n/a | n/a |
| MeiraGTx MGTX | United States | $813M | -13% | +1,366% | 44% | n/a | n/a | n/a |
| Inhibrx Biosciences INBX | United States | $1.02B | -37% | +43% | -6,287% | n/a | n/a | n/a |
| Alto Neuroscience ANRO | United States | $1.04B | +25% | n/a | n/a | n/a | n/a | n/a |
| Wuhan Keqian Biology 688526.SS | China | $780M | -24% | -22% | 20% | 19.4× | 7.8% | +2.4% |
| Guangzhou Wondfo Biotech 300482.SZ | China | $1.05B | -18% | -24% | -2% | 28.4× | 14.3% | -5.8% |
| Daan Gene 002030.SZ | China | $1.05B | -17% | +1% | -81% | n/a | 4.8% | -32.3% |
| Monte Rosa Therapeutics GLUE | United States | $775M | -51% | -61% | -214% | n/a | n/a | n/a |
| Syndax Pharmaceuticals SNDX | United States | $771M | -57% | +160% | -62% | n/a | n/a | n/a |
| Duality Biotherapeutics 9606.HK | Hong Kong | $1.06B | -58% | -5% | -181% | n/a | n/a | n/a |
| Nanjing Leads Biolabs 9887.HK | Hong Kong | $764M | -50% | n/a | -108% | n/a | n/a | n/a |
| Inventiva IVA.PA | France | $763M | -36% | -100% | -307,063% | n/a | n/a | n/a |